Fabio
7.7 KiB
type, title, description, jurisdiction, legislature, session, identifier, citation, classification, subjects, status, primary_sponsors, version_count, action_count, vote_count, first_action, last_action, source, source_identifier, source_url, source_hash, vintage, source_snapshot, retrieved_at, confidence, tags
| type | title | description | jurisdiction | legislature | session | identifier | citation | classification | subjects | status | primary_sponsors | version_count | action_count | vote_count | first_action | last_action | source | source_identifier | source_url | source_hash | vintage | source_snapshot | retrieved_at | confidence | tags | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bill | Patient Access to Compounded Medical Items | The act provides that, if the action is undertaken in accordance with applicable federal and state law:A licensed person may compound a drug or device in the state;A state-licensed pharmacy or a distribution facility registered with the federal food and drug administration (licensed 503B outsourcing facility) may supply a compounded drug or device to a licensed health-care provider, pharmacy, facility, or organization; andA licensed health-care provider, pharmacy, facility, or organization may obtain, dispense, or administer a compounded drug or device supplied by a state-licensed pharmacy or a licensed 503B outsourcing facility. In addition, the act prohibits the state board of pharmacy from adopting rules that are more restrictive than federal or state law regarding the compounding of drugs or devices by licensed 503B outsourcing facilities. Current law exempts drugs that are intended solely for investigational use by experts qualified by scientific training and experience and that are plainly labeled for investigational use only from the sales and delivery prohibition for new drugs. The act also exempts from the prohibition:Drugs that are reviewed by an institutional review board and plainly labeled for investigational use only; andCompounded drugs and devices if the compounding of the drug or device is undertaken in accordance with applicable federal and state law.(Note: This summary applies to this bill as enacted.) | us/states/co | Colorado General Assembly | 2026A | HB 1262 | Colorado HB 1262 (2026A) |
|
|
enacted |
|
7 | 15 | 8 | 2026-02-19 | 2026-06-02 | openstates | ocd-bill/4489566d-3949-41d3-afaa-83ee89e34480 | https://leg.colorado.gov/bills/HB26-1262 | aae1565d96ddfc156a8afdb5a2ed67444d2c079aa90c30fa2569da9880f73d5f | 2026-07-01 | https://data.openstates.org/daily/2026-07-01/public.pgdump | 2026-07-06 | reported |
|
Colorado HB 1262 (2026A) — Patient Access to Compounded Medical Items
The act provides that, if the action is undertaken in accordance with applicable federal and state law:A licensed person may compound a drug or device in the state;A state-licensed pharmacy or a distribution facility registered with the federal food and drug administration (licensed 503B outsourcing facility) may supply a compounded drug or device to a licensed health-care provider, pharmacy, facility, or organization; andA licensed health-care provider, pharmacy, facility, or organization may obtain, dispense, or administer a compounded drug or device supplied by a state-licensed pharmacy or a licensed 503B outsourcing facility. In addition, the act prohibits the state board of pharmacy from adopting rules that are more restrictive than federal or state law regarding the compounding of drugs or devices by licensed 503B outsourcing facilities. Current law exempts drugs that are intended solely for investigational use by experts qualified by scientific training and experience and that are plainly labeled for investigational use only from the sales and delivery prohibition for new drugs. The act also exempts from the prohibition:Drugs that are reviewed by an institutional review board and plainly labeled for investigational use only; andCompounded drugs and devices if the compounding of the drug or device is undertaken in accordance with applicable federal and state law.(Note: This summary applies to this bill as enacted.)
Version chain
The bill's text revisions, in order — the diff chain from filing to enrollment.
- Introduced (filed) — source
- Engrossed (committee substitute) — source
- Final Act (committee substitute) — source
- Reengrossed (committee substitute) — source
- Rerevised (committee substitute) — source
- Revised (committee substitute) — source
- Signed Act (committee substitute) — source
Votes
- BILL — pass (pass) · lower
- Adopt amendment L.007 (Attachment E). — pass (pass) · upper
- REPASS — pass (pass) · upper
- AMD (H.001) — fail (fail) · lower
- Refer House Bill 26-1262 to the Committee of the Whole. — pass (pass) · lower
- AMD (H.002) — fail (fail) · lower
- CONCUR — pass (pass) · upper
- Refer House Bill 26-1262, as amended, to the Committee of the Whole and with a recommendation that it be placed on the consent calendar. — pass (pass) · upper
Sponsors
- D. Roberts — primary (person)
- K. Stewart — primary (person)
- M. Ball — primary (person)
- R. Stewart — primary (person)
- B. Marshall — cosponsor (person)
- B. Titone — cosponsor (person)
- C. Clifford — cosponsor (person)
- C. Espenoza — cosponsor (person)
- E. Hamrick — cosponsor (person)
- E. Sirota — cosponsor (person)
- J. Bacon — cosponsor (person)
- J. Jackson — cosponsor (person)
- J. Joseph — cosponsor (person)
- J. McCluskie — cosponsor (person)
- J. Phillips — cosponsor (person)
- K. Brown — cosponsor (person)
- K. McCormick — cosponsor (person)
- K. Nguyen — cosponsor (person)
- L. García — cosponsor (person)
- L. Smith — cosponsor (person)
- M. Duran — cosponsor (person)
- M. Lindsay — cosponsor (person)
- M. Rutinel — cosponsor (person)
- N. Ricks — cosponsor (person)
- R. Weinberg — cosponsor (person)
- S. Lieder — cosponsor (person)
Timeline
The legislative action history — every referral, reading, and vote.
- 2026-06-02 Governor Signed
executive-signature - 2026-05-22 Sent to the Governor
executive-receipt - 2026-05-22 Signed by the President of the Senate
passage - 2026-05-22 Signed by the Speaker of the House
passage - 2026-04-21 House Considered Senate Amendments - Result was to Concur - Repass
- 2026-04-20 House Considered Senate Amendments - Result was to Laid Over Daily
- 2026-04-17 Senate Third Reading Passed - No Amendments
passage, reading-3 - 2026-04-16 Senate Second Reading Passed with Amendments - Committee
reading-2 - 2026-04-14 Senate Second Reading Laid Over to 04/16/2026 - No Amendments
- 2026-04-09 Senate Committee on Health & Human Services Refer Amended - Consent Calendar to Senate Committee of the Whole
committee-passage - 2026-03-19 Introduced In Senate - Assigned to Health & Human Services
introduction - 2026-03-16 House Third Reading Passed - No Amendments
passage, reading-3 - 2026-03-13 House Second Reading Special Order - Passed with Amendments - Floor
- 2026-03-10 House Committee on Health & Human Services Refer Unamended to House Committee of the Whole
committee-passage, referral-committee - 2026-02-19 Introduced In House - Assigned to Health & Human Services
introduction
Source
OpenStates / OpenCivicData bulk snapshot 2026-07-01; origin ocd-bill/4489566d-3949-41d3-afaa-83ee89e34480. Confidence: reported (aggregated from official Colorado legislature records).